APOE and Alzheimer disease: TIM exhibits impaired Aβ clearance and altered cell–cell communication during aducanumab treatment [259], suggesting that it may contribute to AD risk and pathology, particularly in APOE4 carriers and the elderly, making it a potential therapeutic target.